Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Operating Leases (2019 - 2024)

Arcadia Biosciences filings provide 6 years of Operating Leases readings, the most recent being $11000.0 for Q2 2024.

  • On a quarterly basis, Operating Leases fell 97.93% to $11000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $11000.0, a 97.93% decrease, with the full-year FY2023 number at $155000.0, down 84.61% from a year prior.
  • Operating Leases hit $11000.0 in Q2 2024 for Arcadia Biosciences, down from $21000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.7 million in Q2 2021 to a low of $11000.0 in Q2 2024.
  • Median Operating Leases over the past 5 years was $1.6 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Operating Leases: soared 284.41% in 2020 and later crashed 97.93% in 2024.
  • Arcadia Biosciences' Operating Leases stood at $5.4 million in 2020, then crashed by 58.8% to $2.2 million in 2021, then crashed by 54.64% to $1.0 million in 2022, then tumbled by 84.61% to $155000.0 in 2023, then plummeted by 92.9% to $11000.0 in 2024.
  • The last three reported values for Operating Leases were $11000.0 (Q2 2024), $21000.0 (Q1 2024), and $155000.0 (Q4 2023) per Business Quant data.